Miguel Ángel Seguí

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers

Roy R. L. Bastien, Álvaro Rodríguez-Lescure, Mark Ebbert et al. · BMC Medical Genomics · 2012 · 343 citations · Full text

Medicine, Cancer Biology, Oncology +17

Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Miguel Martín, Álvaro Rodríguez-Lescure, A. Ruiz et al. · JNCI Journal of the National Cancer Institute · 2008 · 239 citations · Full text

Medicine, Oncology, Pharmacology +15

Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer

Miguel Martín, Miguel Ángel Seguí, Antonio Antón et al. · New England Journal of Medicine · 2010 · 208 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

Miguel Martín, Aňa Lluch, Miguel Ángel Seguí et al. · Annals of Oncology · 2006 · 204 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

Aňa Lluch, Carlos H. Barrios, Laura Torrecillas et al. · Journal of Clinical Oncology · 2019 · 153 citations · Full text

Medicine, Oncology, Pharmacology +17